Predictors of recovery of ovarian function during aromatase inhibitor therapy

Annals of Oncology

Volumn 24, Issue 8, 2013, Pages 2011-2016

  Henry, N L ^a   Xia, R ^b   Banerjee, M ^b   Gersch, C ^a   McConnell, D ^b   Giacherio, D ^c   Schott, A F ^a   Pearlman, M ^c   Stearns, V ^d   Partridge, A H ^e   Hayes, D F ^a  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Aromatase inhibitor; Breast cancer; Chemotherapy induced ovarian failure; Estradiol; Ovarian function

Indexed keywords

ANASTROZOLE; ESTRADIOL; FOLLITROPIN; HORMONE RECEPTOR; INHIBIN B;

ADULT; AMENORRHEA; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED OVARIAN FAILURE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONVALESCENCE; DRUG EFFECT; DRUG SAFETY; DRUG WITHDRAWAL; ESTRADIOL BLOOD LEVEL; FEMALE; FOLLITROPIN BLOOD LEVEL; HORMONE DETERMINATION; HUMAN; MAJOR CLINICAL STUDY; OVARY FUNCTION; OVARY INSUFFICIENCY; POSTMENOPAUSE; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT OUTCOME; VAGINA BLEEDING;

AROMATASE INHIBITOR; BREAST CANCER; CHEMOTHERAPY-INDUCED OVARIAN FAILURE; ESTRADIOL; OVARIAN FUNCTION;

ADULT; AMENORRHEA; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; ESTRADIOL; FEMALE; HUMANS; MIDDLE AGED; NITRILES; OVARY; PRIMARY OVARIAN INSUFFICIENCY; PROSPECTIVE STUDIES; RECEPTORS, ESTROGEN; TAMOXIFEN; TRIAZOLES; UTERINE HEMORRHAGE;

EID: 84881235274     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt149     Document Type: Article

References (12)

1. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687-1717.
2. Dowsett M, Cuzick J, Ingle J et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 2010; 28: 509-518.
3. Petrek JA, Naughton MJ, Case LD et al. Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study. J Clin Oncol 2006; 24: 1045-1051.
4. Smith IE, Dowsett M, Yap Y-S et al. Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines. JCO 2006; 24: 2444-2447.
5. Stanczyk FZ, Lee JS, Santen RJ. Standardization of steroid hormone assays: why, how, and when? Cancer Epidemiol Biomarkers Prev 2007; 16: 1713-1719.
6. Sowers MR, Eyvazzadeh AD, McConnell D et al. Anti-mullerian hormone and inhibin B in the definition of ovarian aging and the menopause transition. J Clin Endocrinol Metab 2008; 93: 3478-3483.
7. Nelson RE, Grebe SK, DJ OK, Singh RJ. Liquid chromatography-tandem mass spectrometry assay for simultaneous measurement of estradiol and estrone in human plasma. Clin Chem 2004; 50: 373-384.
8. Santen RJ, Demers L, Ohorodnik S et al. Superiority of gas chromatography/ tandem mass spectrometry assay (GC/MS/MS) for estradiol for monitoring of aromatase inhibitor therapy. Steroids 2007; 72: 666-671.
9. Guerrero A, Gavila J, Folkerd E et al. Incidence and predictors of ovarian function recovery (OFR) in breast cancer (BC) patients with chemotherapy-induced amenorrhea (CIA) who switched from tamoxifen to exemestane. Ann Oncol 2013; 24: 674-679.
10. Dowsett M, Folkerd E. Deficits in plasma oestradiol measurement in studies and management of breast cancer. Breast Cancer Res 2005; 7: 1-4.
11. Anderson RA, Cameron DA. Pretreatment serum anti-mullerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast cancer. J Clin Endocrinol Metab 2011; 96: 1336-1343.
12. Goss PE, Ingle JN, Martino S et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003; 349: 1793-1802.